公开(公告)号：US11427561B2

公开(公告)日：2022-08-30

申请号：US16071200

申请日：2017-01-18

Applicant: BIOGEN MA INC.

Inventor： Timothy Chan ,  Kevin M. Guckian ,  Tracy Jenkins ,  Jermaine Thomas ,  Jeffrey Vessels ,  Gnanasambandam Kumaravel ,  Robert Meissner ,  Joseph P. Lyssikatos ,  Brian Lucas ,  Irina Leaf ,  Jeremy Duffield ,  Nathan Genung

IPC: C07D401/14 ,  A61K45/06

Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production. Formula (I) The compounds are IRAK-4 inhibitors useful for treating an inflammatory disease, an autoimmune disease, cancer, a cardiovascular disease, a disease of the central nervous system, a disease of the skin, an ophthalmic disease and condition, and a bone disease.

公开(公告)号：US09850206B2

公开(公告)日：2017-12-26

申请号：US14443912

申请日：2013-11-20

Applicant: BIOGEN MA INC.

Inventor： Hairuo Peng ,  Edward Yin-Shiang Lin ,  Jianhua Chao ,  Zhili Xin ,  Bin Ma ,  Kevin Guckian ,  Timothy Chan ,  Gnanasambandam Kumaravel ,  Arthur G. Taveras

IPC: C07D211/22 ,  C07D213/74 ,  C07D401/12 ,  C07D237/22 ,  C07D239/47 ,  C07D207/08 ,  C07D211/56 ,  C07D211/62 ,  C07D295/15 ,  C07D295/155 ,  C07D211/70 ,  A61K31/451 ,  A61K31/4545 ,  A61K31/495 ,  A61K31/501 ,  A61K31/506 ,  A61K45/06 ,  C07D401/04 ,  C07D403/04

CPC classification number: C07D211/22 ,  A61K31/451 ,  A61K31/4545 ,  A61K31/495 ,  A61K31/501 ,  A61K31/506 ,  A61K45/06 ,  C07D207/08 ,  C07D211/56 ,  C07D211/62 ,  C07D211/70 ,  C07D213/74 ,  C07D237/22 ,  C07D239/47 ,  C07D295/15 ,  C07D295/155 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04

Abstract: Compounds of formula (I) wherein: X is —O—, —S(O)r—, —CH2—, or —NR—, wherein r is 0, 1, or 2; X1, X2, and X5 are each independently CR7 or N; one of X3 or X4 is C and is attached by a single bond to -L-, and the other is CR7 or N, provided that no more than three of X1, X2, X3, X or X5 are N; Ring A is monocyclic C5-6scycloalkyl or a 5- to 6-membered monocyclic heterocyclyl comprising from 1 to 5 heteroatoms independently selected from N, S, or O; wherein Ring A is further optionally substituted with from 1 to 3 R4; provided that Ring A is not morpholinyl, thiomorpholinyl or tetrahydro-2H-pyranyl; L is a bond, —O—, —NR—, —S(O)n—, —CH2—, or —C(O)—, wherein n is 0, 1, or 2; 1 2 L1 is an C1-8alkylene, C3-scycloalkylene, —CH2-L2-, or a 3- to 8-membered heterocyclylene comprising 1 to 5; R1 is C6-20alkyl or a monocyclic C3-8cycloalkyl; wherein said C3-8cycloalkyl is substituted with at least one R6 and may be optionally substituted with from 1 to 5 additional R6 substituents, wherein R6 for each occurrence is independently selected; and R2 is —C(O)OR3, —C(O)N(R3)—S(O)2R3, —S(O)2OR3, —C(O)NHC(O)R3, —Si(O)OH, —B(OH)2, —N(R3)S(O)2R3, —S(O)2N(R3)2, —O—P(O)(OR3)2, or —P(O)(OR3)2, —CN, —S(O)2NHC(O)R3, —C(O)NHS(O)2R3, —C(O)NHOH, —C(O)NHCN, —CH(CF3)OH, —C(CF3)2OH, or a selected heteroaryl or heterocyclyl; and pharmaceutically acceptable salts thereof, can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).

公开(公告)号：US09771326B2

公开(公告)日：2017-09-26

申请号：US14443944

申请日：2013-11-20

Applicant: BIOGEN MA INC.

Inventor： Hairuo Peng ,  Zhili Xin ,  Lihong Sun ,  Timothy Chan ,  Gnanasambandam Kumaravel ,  Arthur G. Taveras

IPC: C07D211/62 ,  C07D401/10 ,  C07D237/14 ,  C07D215/14 ,  C07D401/04 ,  C07D239/34 ,  C07D417/04 ,  C07D417/06 ,  C07C229/14 ,  C07D249/06 ,  C07C229/48 ,  C07C229/50 ,  C07D487/04 ,  C07D205/04 ,  C07D207/16 ,  C07D277/28 ,  C07D209/44 ,  C07D211/34 ,  C07D211/46 ,  C07D213/38 ,  C07D213/65 ,  A61K31/196 ,  A61K31/197 ,  A61K31/397 ,  A61K31/40 ,  A61K31/427 ,  A61K31/445 ,  A61K31/4545 ,  A61K31/50 ,  A61K31/505 ,  A61K45/06

CPC classification number: C07D211/62 ,  A61K31/196 ,  A61K31/197 ,  A61K31/397 ,  A61K31/40 ,  A61K31/427 ,  A61K31/445 ,  A61K31/4545 ,  A61K31/50 ,  A61K31/505 ,  A61K45/06 ,  C07B2200/07 ,  C07C229/14 ,  C07C229/48 ,  C07C229/50 ,  C07C2601/14 ,  C07C2602/44 ,  C07D205/04 ,  C07D207/16 ,  C07D209/44 ,  C07D211/34 ,  C07D211/46 ,  C07D213/38 ,  C07D213/65 ,  C07D215/14 ,  C07D237/14 ,  C07D239/34 ,  C07D249/06 ,  C07D277/28 ,  C07D401/04 ,  C07D401/10 ,  C07D417/04 ,  C07D417/06 ,  C07D487/04

Abstract: Compounds of formula (I), and pharmaceutically acceptable salts thereof, can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).

公开(公告)号：US20170204093A1

公开(公告)日：2017-07-20

申请号：US15326740

申请日：2015-07-17

Applicant: BIOGEN MA INC.

Inventor： Timothy Chan ,  Kevin Guckian ,  Tracy Jenkins ,  Jermaine Thomas ,  Jeffery Vessels ,  Gnanasambandam Kumaravel ,  Robert Meissner ,  Joseph Lyssikatos ,  Brian Lucas ,  Irina Leaf ,  Jeremy Duffield

IPC: C07D471/04 ,  C07D401/12 ,  C07D405/14 ,  C07D413/14 ,  C07B59/00 ,  C07D401/14 ,  C07D417/14

CPC classification number: C07D471/04 ,  A61K31/416 ,  A61P13/12 ,  C07B59/002 ,  C07B2200/05 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.

公开(公告)号：US20190248787A1

公开(公告)日：2019-08-15

申请号：US16271497

申请日：2019-02-08

Applicant: BIOGEN MA INC.

Inventor： Timothy Chan ,  Kevin Guckian ,  Tracy Jenkins ,  Jermaine Thomas ,  Jeffery Vessels ,  Gnanasambandam Kumaravel ,  Robert Meissner ,  Joseph Lyssikatos ,  Brian Lucas ,  Irina Leaf ,  Jeremy Duffield

IPC: C07D471/04 ,  C07D417/14 ,  C07D413/14 ,  A61K31/416 ,  C07D401/12 ,  C07B59/00 ,  C07D405/14 ,  C07D401/14

Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.

公开(公告)号：US10246456B2

公开(公告)日：2019-04-02

申请号：US15326740

申请日：2015-07-17

Applicant: BIOGEN MA INC.

Inventor： Timothy Chan ,  Kevin Guckian ,  Tracy Jenkins ,  Jermaine Thomas ,  Jeffery Vessels ,  Gnanasambandam Kumaravel ,  Robert Meissner ,  Joseph Lyssikatos ,  Brian Lucas ,  Irina Leaf ,  Jeremy Duffield

IPC: C07D471/04 ,  C07D413/14 ,  C07D405/14 ,  C07D401/14 ,  A61K31/416 ,  A61P13/12 ,  C07B59/00 ,  C07D401/12 ,  C07D417/14

Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.

公开(公告)号：US20210188809A1

公开(公告)日：2021-06-24

申请号：US16071200

申请日：2017-01-18

Applicant: BIOGEN MA INC.

Inventor： Timothy Chan ,  Kevin Guckian ,  Tracy Jenkins ,  Jermaine Thomas ,  Jeffrey Vessels ,  Gnanasambandam Kumaravel ,  Robert Meissner ,  Joseph P. Lyssikatos ,  Brian Lucas ,  Irina Leaf ,  Jeremy Duffield ,  Nathan Genung

IPC: C07D401/14 ,  A61K45/06

Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production. Formula (I) The compounds are IRAK-4 inhibitors useful for treating an inflammatory disease, an autoimmune disease, cancer, a cardiovascular disease, a disease of the central nervous system, a disease of the skin, an ophthalmic disease and condition, and a bone disease.

公开(公告)号：US10577367B2

公开(公告)日：2020-03-03

申请号：US16271497

申请日：2019-02-08

Applicant: BIOGEN MA INC.

Inventor： Timothy Chan ,  Kevin Guckian ,  Tracy Jenkins ,  Jermaine Thomas ,  Jeffery Vessels ,  Gnanasambandam Kumaravel ,  Robert Meissner ,  Joseph Lyssikatos ,  Brian Lucas ,  Irina Leaf ,  Jeremy Duffield

IPC: C07D401/14 ,  C07D487/04 ,  A61K31/416 ,  A61K31/437 ,  A61K31/44 ,  A61P13/12 ,  A61P19/02 ,  C07D471/04 ,  C07D405/14 ,  C07D413/14 ,  C07B59/00 ,  C07D401/12 ,  C07D417/14

Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.